Cytori Therapeutics (NASDAQ:CYTX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Tuesday, February 13th.
According to Zacks, “Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company’s preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient’s own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients. “
CYTX has been the topic of a number of other reports. B. Riley reiterated a “hold” rating on shares of Cytori Therapeutics in a research report on Tuesday, November 7th. Maxim Group set a $5.00 target price on shares of Cytori Therapeutics and gave the stock a “buy” rating in a report on Monday, November 13th. Finally, ValuEngine upgraded shares of Cytori Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company. Cytori Therapeutics currently has an average rating of “Hold” and a consensus target price of $2.30.
Shares of Cytori Therapeutics (NASDAQ CYTX) traded up $0.02 on Tuesday, reaching $0.36. 1,501,900 shares of the company were exchanged, compared to its average volume of 2,146,952. The stock has a market capitalization of $11.84, a P/E ratio of -0.39 and a beta of 3.11. Cytori Therapeutics has a 1-year low of $0.22 and a 1-year high of $2.08.
In related news, major shareholder Bank Sa Swissquote sold 100,000 shares of Cytori Therapeutics stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $0.38, for a total value of $38,000.00. Following the completion of the sale, the insider now directly owns 5,496,655 shares in the company, valued at approximately $2,088,728.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Ag Postfinance sold 236,155 shares of Cytori Therapeutics stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $0.34, for a total value of $80,292.70. Following the completion of the sale, the insider now owns 5,311,451 shares of the company’s stock, valued at $1,805,893.34. The disclosure for this sale can be found here. Insiders sold 695,767 shares of company stock valued at $231,951 in the last ninety days. 1.90% of the stock is currently owned by insiders.
Several institutional investors have recently added to or reduced their stakes in CYTX. Perkins Capital Management Inc. grew its stake in shares of Cytori Therapeutics by 134.0% during the 4th quarter. Perkins Capital Management Inc. now owns 2,136,041 shares of the biotechnology company’s stock valued at $644,000 after acquiring an additional 1,223,046 shares during the period. Sabby Management LLC grew its stake in shares of Cytori Therapeutics by 28.0% during the 2nd quarter. Sabby Management LLC now owns 1,626,807 shares of the biotechnology company’s stock valued at $1,789,000 after acquiring an additional 355,504 shares during the period. Finally, Vanguard Group Inc. grew its stake in shares of Cytori Therapeutics by 81.9% during the 2nd quarter. Vanguard Group Inc. now owns 612,304 shares of the biotechnology company’s stock valued at $674,000 after acquiring an additional 275,653 shares during the period. Institutional investors and hedge funds own 10.41% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Zacks Investment Research Downgrades Cytori Therapeutics (NASDAQ:CYTX) to Sell” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/23/zacks-investment-research-lowers-cytori-therapeutics-cytx-to-sell.html.
About Cytori Therapeutics
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
Get a free copy of the Zacks research report on Cytori Therapeutics (CYTX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.